A phase 2 study of carperitide for kidney injury associated with allogeneic hematopoietic stem cell transplantatio
Phase 2
- Conditions
- allogeneic hematopoietic stem cell transplantation
- Registration Number
- JPRN-UMIN000028485
- Lead Sponsor
- Gunma University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1. Contraindicated] in the patient [attachment document with serious low blood pressure or the cardiogenic shock 2. Contraindicated] in the patient [attachment document with the RV myocardial infarction 3. Contraindicated] in the patient [attachment document with the dehydration 6. Chronic dialysis patient 7.ACE inhibitor, ARB treatment started within two weeks 8.patient received contrast media within three days 10,The patient who is inappropriate judged by the chief physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method